InvestorsHub Logo
Followers 2
Posts 8
Boards Moderated 0
Alias Born 02/10/2002

Re: None

Friday, 09/24/2021 4:40:56 PM

Friday, September 24, 2021 4:40:56 PM

Post# of 513
I don't visit ihub much, but came back when EDSA jumped last Monday. I notice there isn't much discussion of the technical viability of the EB05 TLR4 antibody as a treatment for ARDS. So, I hought I'd post this link to an independent review in case anyone cared. In short, TLR4 is looking like a critical checkpoint in ARDS from Covid-19 (as well as other causes). Expect other biotechs to start jumpig on the bandwagon. EDSA is a couple years ahead, and if EBO5 is commercialized, it will be SOC, so it will be hard to recruit for cometing trials.
Review of TLR4 in Covid pathology:
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8095161/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EDSA News